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Increasing energy expenditure through activation of
endogenous brown adipose tissue (BAT) is a poten-
tial approach to treat obesity and diabetes. The class
of b3-adrenergic receptor (AR) agonists stimulates
rodent BAT, but this activity has never been demon-
strated in humans. Here we determined the ability of
200 mg oral mirabegron (Myrbetriq, Astellas Pharma,
Inc.), a b3-AR agonist currently approved to treat
overactive bladder, to stimulate BAT as compared
to placebo. Mirabegron led to higher BAT metabolic
activity as measured via 18F-fluorodeoxyglucose
(18F-FDG) using positron emission tomography
(PET) combined with computed tomography (CT) in
all twelve healthy male subjects (p = 0.001), and it
increased resting metabolic rate (RMR) by 203 ±
40 kcal/day (+13%; p = 0.001). BATmetabolic activity
was also a significant predictor of the changes in
RMR (p = 0.006). Therefore, a b3-AR agonist can
stimulate human BAT thermogenesis and may be a
promising treatment for metabolic disease.
INTRODUCTION
Obesity and metabolic disease result when energy intake
consistently exceeds energy expenditure. One appealing new
target for treatment is the activation of brown adipose tissue
(BAT), an organ recently found to be functional in adult humans
(van Marken Lichtenbelt et al., 2009; Cypess et al., 2009; Virta-
nen et al., 2009; Zingaretti et al., 2009; Saito et al., 2009). Cold
exposure causes the sympathetic nervous system to release
norepinephrine and induce human BAT thermogenesis through
consumption of fatty acids and glucose. In addition to improving
energy balance, rodent models have shown that chronic stimu-
lation of BAT leads to improved glucose tolerance and the
release of adipokines that beneficially regulate metabolism (Bar-
telt et al., 2011; Hondares et al., 2011). Unfortunately, nonspe-
cific sympathomimetic drugs cannot stimulate human BATCwithout marked effects on the cardiovascular system (Cypess
et al., 2012; Vosselman et al., 2012; Carey et al., 2013).
One area of focus for over two decades has been the stimula-
tion of BAT energy expenditure and nutrient consumption
through activation of the b3-adrenergic receptor (AR), which is
expressed in humans on the surfaces of brown and white adipo-
cytes, urinary bladder, and potentially other tissues (Virtanen
et al., 2009; Cypess et al., 2013; Ursino et al., 2009). Previous
phase 2 clinical trials with members of this class demonstrated
improved glucose disposal, decreased plasma triglycerides,
and increased RMR (Cawthorne et al., 1992; Weyer et al.,
1998; Larsen et al., 2002; Redman et al., 2007). Nevertheless,
none of these drugs ultimately achieved regulatory approval for
the treatment of obesity or metabolic disease. Reasons for this
lack of success have been attributed to multiple factors,
including poor oral bioavailability and substantial cross-reac-
tivity with the b1-AR that caused undesirable cardiovascular
effects (Arch, 2011). More fundamentally, it was unknown if the
b3-AR agonists could stimulate human BAT. This issue is still
unresolved, because these drugswere evaluated prior to the dis-
coveries of functional human BAT and how to measure its meta-
bolic activity via prospective 18F-fluorodeoxyglucose (18F-FDG)
PET/CT imaging (van Marken Lichtenbelt et al., 2009; Virtanen
et al., 2009; Muzik et al., 2013; Yoneshiro et al., 2013; van der
Lans et al., 2013). Recently, the new b3-AR agonist mirabegron
was approved for treatment of overactive bladder. In addition to
having satisfactory bioavailability (Malik et al., 2012), mirabegron
has a higher in vitro binding affinity for the human b3-AR
compared to other members of its class (Takasu et al., 2007),
as well as the mixed sympathomimetic ephedrine (Vansal and
Feller, 1999), making it a promising candidate.RESULTS AND DISCUSSION
Effects of Acute Cold Exposure on BAT, RMR, and Vital
Signs
To test the ability of mirabegron to acutely stimulate human BAT,
we wanted to evaluate its efficacy in subjects who were already
known to have detectable BAT, thereby reducing the likelihood
of a false-negative finding (Cypess et al., 2012; Carey et al.,
2013). Fifteen eligible subjects were screened first with coldell Metabolism 21, 33–38, January 6, 2015 ª2015 Elsevier Inc. 33
Table 1. Clinical Characteristics of Subjects
Characteristica (Units) Valueb
Age (years) 22.2 ± 0.6
Height (cm) 177 ± 2
Weight (kg) 71.3 ± 2.4
Body-mass Index (kg/m2) 22.7 ± 0.5
Waist-hip Ratio 0.85 ± 0.01
Body Fatc (kg) 13.4 ± 0.8
Fat-free Massc (kg) 58.6 ± 2.7
Systolic Blood Pressure (mmHg) 112 ± 2
Diastolic Blood Pressure (mmHg) 68 ± 2
Heart Rate (bpm) 57 ± 2
Resting Metabolic Rate (kcal/day) 1,573 ± 56
See also Figure S1.
aBaseline values determined prior to the dosing of mirabegron.
bValues are mean ± SEM.
cMeasured on average 2 weeks prior to the dosing of mirabegron.exposure, and twelve had detectable BAT (Supplemental Exper-
imental Procedures; Figure S1A available online). The amount of
BAT activity, based on the standard uptake value (SUV), was
comparable to that reported in other studies using lower doses
of radiotracer (Vosselman et al., 2012). In these twelve subjects
(Table 1), cold exposure increased RMR (128 ± 32 kcal/day,
or +8%) (p = 0.001), systolic blood pressure (BP), and diastolic
BP; decreased heart rate (Figures S1B–S1E); and led to metab-
olite concentrations consistent with what we have previously re-
ported (Cypess et al., 2012). Safety considerations limited the
subjects to three PET/CT scans each, so we could evaluate
only one dose of mirabegron in comparison to placebo. We
selected 200 mg since this dose has a higher efficacy than the
currently approved dose of 50 mg for reducing the symptoms
of overactive bladder and was therefore more likely to have a
detectable effect on BAT metabolic activity. In addition, the
200 mg dosage has been well-tolerated even after 12 weeks of
daily oral administration (Chapple et al., 2013).
Effects of Mirabegron on Tissue Glucose Uptake, RMR,
Vital Signs, and Plasma Metabolites
Compared to placebo, for all twelve subjects BAT glucose
uptake was significantly higher after treatment with mirabegron
(median 132, interquartile range 70–253 ml,SUVmean,g/ml,
p = 0.001) (Figures 1A, 1B, and S2). The principal sites of detect-
able BAT were the cervical-supraclavicular-axillary adipose
tissue depots, but in some subjects, glucose uptake was seen
even in the paraspinal, periaortic, perihepatic, perirenal, and
perisplenic regions. The correlation between drug- and cold-
inducedBAT glucose uptakewas not significant (Figure S3), indi-
cating that it is not consistently reliable to use only onemethod of
stimulation—either cold or mirabegron—to accurately measure
whole-body BAT mass or activity.
Compared to placebo, mirabegron significantly increased
RMR (203 ± 40 kcal/d, or +13%) (p = 0.001), HR (14 ± 3 bpm)
(p = 0.002), and systolic BP (11 ± 2 mmHg) (p = 0.002), but not
diastolic BP (2 ± 1 mmHg) (p = 0.07) (Figures 1C–1F). This
drug-induced stimulation of the cardiovascular system was
considerably lower than what has been reported for broadly34 Cell Metabolism 21, 33–38, January 6, 2015 ª2015 Elsevier Inc.acting sympathomimetics such as ephedrine or isoproterenol,
particularly for the extent of changes seen in RMR (Cypess
et al., 2012; Vosselman et al., 2012; Carey et al., 2013). There
were no unanticipated adverse effects.
Metabolites were drawn 3.5 hr after dosing of mirabegron and
placebo, which was the reported Tmax (Malik et al., 2012). Mira-
begron was detectable in the plasma with a mean concentration
of 310 ± 73 ng/mL (p = 0.001), values comparable to other
studies (Malik et al., 2012). Administration of mirabegron was
notable for inducing higher levels of glucose, nonesterified fatty
acids (NEFAs), b-hydroxybutyrate, insulin, C-peptide, and signif-
icant elevations in HOMA-IR (p = 0.002) (Table S1). Maximal
glucose uptake (SUVmax) was lower in the myocardium, though
it did not achieve significance after applying Bonferroni’s correc-
tion. No apparent differences were seen in the subcutaneous
white adipose tissue (WAT), skeletal muscle, or liver (Figures
2A–2D).
Predictors of Drug-Induced Changes in RMR
Since both BAT and WAT express the b3-AR (Virtanen et al.,
2009), as exploratory analyses, we compared the changes in
RMR with BAT activity and WAT mass. We found a close asso-
ciation between change in RMR and BAT activity stimulated by
mirabegron (p = 0.006) but not placebo (p = 0.17) (Figures 3A
and 3B). There was also a positive relationship between changes
in RMR and body fat mass in response to mirabegron (p = 0.02)
but not placebo (p = 0.64) (Figures 3C and 3D). In contrast, there
were no associations between the change in RMR and the
change in heart rate (R2 = 0.00, p = 0.97), systolic BP (R2 =
0.01, p = 0.14), or fat-free mass (R2 = 0.00, p = 0.96).
A challenge to studying human thermogenesis is determining
the contribution of each organ. Mirabegron increased BAT
glucose uptake, which correlates directly with tissue thermogen-
esis (Ouellet et al., 2012), and the degree of activation accounted
for 50% of the variability in drug-induced changes in RMR. The
amount of BAT thermogenesis in absolute terms must still be
determined, particularly as there may be an important contribu-
tion from nonselective activation of other b-AR’s on other tis-
sues. Nevertheless, our findings indicate that human BAT may
play a role in the thermogenesis associated with b3-AR agonist
treatment as well as exposure to mild cold (Chen et al., 2013).
An intriguing issue is the proportional contribution by the two
different brown adipocyte lineages: the constitutive ‘‘brown’’
adipocytes in the cervical and supraclavicular depots and the
recruitable ‘‘beige/brite’’ adipocytes in the supraclavicular,
abdominal, and other sites (Wu et al., 2012; Sharp et al., 2012;
Lidell et al., 2013; Cypess et al., 2013; Jespersen et al., 2013;
Sacks et al., 2013). Based on the wide distribution of detectable
glucose uptake, it is likely that mirabegron stimulates both kinds
of BAT, though more detailed in vitro studies are required to
quantify what functional differences may exist between these
adipocytes.
Potential Therapeutic Applications of Chronic
Treatment with b3-AR Agonists
An important question remains as to what clinical benefit there
could be from stimulation of human BAT with b3-AR agonists.
Attention has been given to weight loss through increased
energy expenditure as a treatment for obesity. Previous clinical
Figure 1. Metabolic Effects of the b3-AR
Agonist Mirabegron
(A) PET images of a 21-year-old man who was
given placebo (left) or 200mg of the b3-AR agonist
mirabegron (right). Twelve male subjects were
given placebo or 200 mg mirabegron.
(B) BAT metabolic activity as reflected by 18F-FDG
uptake.
(C) Resting metabolic rate.
(D) Heart rate.
(E) Systolic BP.
(F) Diastolic BP.
Each circle represents a single subject, and the
numbers correspond to subject identification num-
ber in Figure S2. The dashes represent the mean.
See also Figure S2.trials of b3-AR agonists did not achieve weight loss within at
most 8 weeks of treatment. This may have been in part because
the doses used were insufficient to activate BAT thermogenesis
(Weyer et al., 1998; Larsen et al., 2002; Redman et al., 2007). At
the 200 mg dose used in the current study, the observed
maximal increase in energy expenditure would lead to an even-
tual weight loss of5 kg in the first year and 10 kg by the end of 3
years (Hall et al., 2011). Though promising, the actual amount of
weight loss would likely be less, since 200 kcal/day was the peak
energy expenditure and not sustained throughout the day.
However, it is important to consider that in rodent models,
treatment with b3-AR agonists chronically can improve glucose
disposal and increase RMR before a reduction in body weight is
seen (de Souza et al., 1997). This distinction between the acute
and chronic effects of treatment with mirabegron applies to the
current study. In the acute setting, we saw a significant increase
in HOMA-IR, a measure of insulin resistance. As with the
changes in heart rate, it is not known if this effect is from off-
target binding to other b-AR’s, and future studies are needed
to determine which metabolic changes are attributable specif-
ically to b3-AR agonists. In the present study, in addition to the
effects onBAT, therewas evidence for b3-AR agonist stimulation
of WAT lipolysis (Kim et al., 2006), which was reflected by the
non-significantly higher levels of serum NEFAs and lower
myocardial glucose uptake that is associated with this change
in fuel availability (Vosselman et al., 2012). Thus, chronic treat-
ment with a b3-AR agonist in humans may improve multiple fac-Cell Metabolism 21, 33–ets of metabolism even in the absence of
weight loss through consumption of lipids
and glucose and also the release of bene-
ficial adipokines (Stanford et al., 2013;
Villarroya et al., 2013).
This study is limited by its small size
and duration. Also, the young, lean,
healthy male subjects with detectable
BAT were selected deliberately for the
purpose of a proof-of-concept study, so
the efficacy of mirabegron needs to be
evaluated in women and other popula-
tions, such as those with different ages
and BMIs. In addition, the changes in
RMR and metabolism were measuredafter administration of a single dose of mirabegron, so we do
not know if chronic treatment would yield the metabolic benefits
seen with other b3-AR agonists. Finally, the decision to use the
more potent 200 mg dose of mirabegron was advantageous in
that all twelve subjects had detectable BAT activity that was
higher than placebo. For this small sample size, the wide range
of BAT activities we observedwas crucial for learningmeaningful
aspects about human BAT physiology. However, the 200 mg
dose was also higher than necessary to selectively activate
only the b3-AR (Takasu et al., 2007; FDA 2012a). As a result,
we observed binding to the b1-AR with resultant tachycardia, a
treatment-emergent adverse event noted in several clinical trials
of mirabegron (Malik et al., 2012; Sacco and Bientinesi, 2012).
Given the acute stimulation of the cardiovascular system, the
long-term safety of this approach must be established. It re-
mains to be determined if the approved daily dose of 50 mg for
overactive bladder, which was associated with smaller effects
on heart rate (FDA 2012b), will sufficiently stimulate BAT growth
and thermogenesis. Given that activation of the myocardial b3-
AR has limited chronotropic effects (Masutani et al., 2013),
concomitant administration of 200 mg mirabegron with a b1-
AR blocker could mitigate the undesirable cardiovascular stimu-
lation. Alternatively, it is possible that the off-target effects may
be satisfactorily reduced by newly designed members of the
class having greater selectivity for the b3-AR.
In summary, we demonstrate that the b3-AR agonist
mirabegron acutely stimulates human BAT thermogenesis and38, January 6, 2015 ª2015 Elsevier Inc. 35
Figure 2. Tissue Glucose Uptake
18F-FDG uptake in the twelve volunteers when given placebo or 200 mg mir-
abegron is shown for different tissues. Each circle represents a single subject.
(A) Myocardium.
(B) Subcutaneous WAT.
(C) Skeletal muscle.
(D) Liver.
See also Table S1.
Figure 3. Predictors of Resting Metabolic Rate
(A) Placebo-induced BAT activity.
(B) Two-hundred milligram mirabegron-induced BAT activity.
(C) Body fat mass with placebo.
(D) Body fat mass with 200 mg mirabegron.
See also Figure S3.increases RMR. Given that mirabegron is already approved for
treatment of overactive bladder, we anticipate that these find-
ings will accelerate the development of pharmacological strate-
gies designed to increase energy expenditure and treat obesity
and metabolic disease.
EXPERIMENTAL PROCEDURES
Additional information canbe found in Supplemental Experimental Procedures.
Study Approval
This clinical trial is registered with ClinicalTrials.gov (NCT01783470) and has
the FDA Investigational New Drug (IND) registration number 116246. It was
approved by the Human Studies Institutional Review Boards of Beth Israel
Deaconess Medical Center (BIDMC) and Joslin Diabetes Center (JDC).
Healthy volunteers were recruited through electronic advertisements and pro-
vided written informed consent.
Study Day
Fifteen subjects underwent cold-activated 18F-FDG PET/CT scanning, con-
sisting of wearing a vest with circulating water set to 14C for 120 min, as
described in Cypess et al. (2012), and twelve had detectable BAT. These
twelve subjects then participated in two more imaging days in which they
were given 200 mg per os mirabegron or placebo control in randomized order
that was unblinded. To reduce the contribution of cold-activated BAT, for the
placebo and mirabegron study days, we maintained the room temperature
above 23C throughout the entire study visit. There was a washout period of
at least 48 hr between each of the three interventions. Given the plasticity of
BAT activity in response to seasonal changes in outdoor temperature, we
restricted the average interval between the subjects’ first and last study to36 Cell Metabolism 21, 33–38, January 6, 2015 ª2015 Elsevier Inc.28.1 ± 7.4 days. Vital signs, body composition, and metabolites were
measured as described previously (Cypess et al., 2012).
Measurement of Plasma Mirabegron Concentration
All reagents were HPLC grade. For an internal standard, a 1,000 pg/mL stock
solution of [13C6]-Mirabegron (Alsachim) was dissolved in methanol (Fisher
Scientific). A total of 20 ml (20,000 pg) of this standard was added to 500 ml
of the subjects’ plasma. For an ion-pairing agent, we added 400 ml of 20 mM
ammonium acetate (Sigma). Liquid-liquid extraction of mirabegron and the
standard was performed using 3 ml diethyl-ether (Sigma), and the solution
was mixed at room temperature for 10 min. The phases were separated
through centrifugation for 5 min at 2,361 3 g at room temperature. The upper
organic phase was isolated and dried under a stream of nitrogen at room tem-
perature. The precipitate was resuspended in 1.75 ml methanol and then dried
under vacuum at room temperature.
LC-MS/MS Analyses of Mirabegron
An Agilent 6460 LC-MS/MS triple quadrupole mass spectrometer, coupled to
a 1290 uHPLC and atmospheric chemical ionization (APCI), was used for the
detection and quantitation of mirabegron in positive ion mode using a multiple
reaction monitoring approach. An isotopologue of mirabegron [13C6] was used
an internal standard. More comprehensive experimental details are provided in
the Supplemental Experimental Procedures.
Sample Size Calculation
The primary hypothesis was that BAT activity following a single dose of 200mg
mirabegron would be significantly different from that following placebo. BAT
activity was considered as a continuous variable, and each subject was his
own paired control. Since we were conducting a pilot study with no prior
data on the effects of mirabegron on human BAT, we used existing data
from our prior studies of cold-exposedmen to determine the detectable differ-
ence between placebo and mirabegron based on a predetermined sample
size. Additional details can be found in the Supplemental Experimental
Procedures.
Statistical Analysis
We analyzed the data using JMP Pro 9.0.0 software (SAS Institute, Inc.). Since
the sample size of twelve subjects limited the ability to demonstrate that mea-
surements were normally distributed, we used the nonparametric Wilcoxon
sign-ranks test to assess the primary and secondary endpoints. All p values
presented are two tailed. p values% 0.05 were considered to indicate statis-
tical significance for the primary outcome. For the secondary endpoints,
p values% 0.002were considered significant based on aBonferroni correction
for 21 variables (RMR, systolic BP, diastolic BP, and HR; glucose uptake in
myocardium, WAT, skeletal muscle, and liver; and blood concentrations of
glucose, NEFAs, lactic acid, b-hydroxybutyrate, insulin, C-peptide, HOMA-
IR, glucagon, norepinephrine, cortisol, TSH, free T4, and total T3). Drug- and
cold-induced changes in BAT glucose uptake were correlated using
Spearman’s r. The study had >80% power (a = 0.05) to detect a difference
in the primary outcome between mirabegron and placebo treatment equal to
20% of the effect of cold.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.cmet.2014.12.009.
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